Drug intelligence / Profile preview

imetelstat + cytarabine + veliparib

Development stage: Unknown
Lead developer: Geron
Administration: Intravenous, Subcutaneous, Intrathecal

Overview

This appears to be a three-drug combination regimen. Based on the individual components: imetelstat is a telomerase inhibitor, cytarabine is a nucleoside analog chemotherapy agent commonly used in leukemia treatment, and veliparib is a PARP inhibitor that delays DNA repair and potentiates cytotoxicity of chemotherapy drugs. However, no clinical trial or study information is available in the provided sources for this specific three-drug combination.

Targets

Telomerase (Human telomerase)PARP2 (Poly (adp-ribose) polymerase 2)

Beyond the preview

Go deeper on imetelstat + cytarabine + veliparib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on imetelstat + cytarabine + veliparib.

Explore the full profile